

**THE *BURKHOLDERIA*
CEPACIA COMPLEX**



**Suggestions for
Prevention and
Infection Control**

Second Edition

*Report of the
UK Cystic Fibrosis
Trust Infection
Control Group*

September 2004

The UK Cystic Fibrosis Trust Infection Control Group

Chairman

Dr James Littlewood OBE Paediatrician & Chairman, Cystic Fibrosis Trust

Members

Mrs Mary Dodd Consultant Physiotherapist, Manchester and Representative Association of Chartered Physiotherapists in Cystic Fibrosis

Professor Stuart Elborn Respiratory Physician, Belfast and Chairman, Cystic Fibrosis Trust Research and Medical Advisory Committees

Professor Duncan Geddes Respiratory Physician, London

Professor John Govan Microbiologist, Edinburgh

Professor C Anthony Hart Microbiologist, Liverpool

Dr David Heaf Paediatrician, Liverpool

Professor Margaret Hodson Respiratory Physician, London

Ms Teresa Jacklin Patient Representative

Dr Andrew Jones Respiratory Physician, Manchester

Dr Susan Madge Nurse Consultant, London
Representative CF Nurse Specialist Group

Dr Tyrone Pitt Microbiologist, London

Ms Hazel Sanders Parent Representative

Dr Martin Walshaw Respiratory Physician, Liverpool

Dr Sarah Walters Epidemiologist, Birmingham

Professor Kevin Webb Respiratory Physician, Manchester

The Group is grateful to:

Mrs Jan Drayton (Cystic Fibrosis Trust) for administrative support.
Mr Alan Larsen, Director of Finance & Operations, Cystic Fibrosis Trust.
Mrs Sandra Kennedy (Publications Manager, Cystic Fibrosis Trust) for help in the production of this document.



11 London Road
Bromley
Kent BR1 1BY
Tel: 020 8464 7211
Fax: 020 8313 0472
enquiries@cftrust.org.uk
www.cftrust.org.uk

© Cystic Fibrosis Trust 2004

THE BURKHOLDERIA CEPACIA COMPLEX

Suggestions for Prevention and Infection Control

Report of the UK Cystic Fibrosis Trust Infection Control Group

CONTENTS

PREFACE

GRADING SCHEME FOR RECOMMENDATIONS

SUMMARY

1. HISTORICAL PERSPECTIVE

2. TAXONOMY OF THE BURKHOLDERIA CEPACIA COMPLEX

3. CLINICAL CONSEQUENCES OF BURKHOLDERIA CEPACIA COMPLEX INFECTION IN PEOPLE WITH CYSTIC FIBROSIS

- 3.1 Lung transplantation
- 3.2 Cepacia syndrome

4. CROSS-INFECTION CONTROL

5. GENERAL ENVIRONMENT AND BURKHOLDERIA CEPACIA COMPLEX

6. TRANSMISSIBILITY MARKERS

7. TRANSIENT INFECTION

8. SUMMARY OF PRESENT CLINICAL KNOWLEDGE OF INDIVIDUAL BURKHOLDERIA CEPACIA COMPLEX SPECIES

- 8.1 *Burkholderia cenocepacia*
- 8.2 *Burkholderia multivorans*
- 8.3 Other *Burkholderia cepacia* complex species

9. OTHER NON-BURKHOLDERIA CEPACIA COMPLEX BURKHOLDERIA SPECIES

9.1 *Burkholderia gladioli*

9.2 *Burkholderia mallei* and *Burkholderia pseudomallei*

10. LABORATORY IDENTIFICATION OF BURKHOLDERIA CEPACIA COMPLEX

11. TREATMENT – RECENT ADVANCES

12. RECOMMENDATIONS TO LIMIT SPREAD

12.1 General

12.2 Segregation of patients according to their microbiological status

12.3 In the outpatient clinic

12.4 Additional recommendations for inpatients

12.5 Away from the hospital

13. RISKS OF VARIOUS FORMS OF SOCIAL CONTACT

13.1 Table: Activities shared with other people with cystic fibrosis: Risk of transmission

14. REFERENCES

PREFACE

In 1999, the UK Cystic Fibrosis Trust Infection Control Group produced a document *A statement on Burkholderia cepacia*. In light of information from recently published studies and a new taxonomy for the *B. cepacia* complex, the UK Cystic Fibrosis Trust Infection Control Group has now extensively revised the original document.

The present document reviews much of the available information on the prevention and control of *B. cepacia* complex infection in people with cystic fibrosis (CF). Some of the recommendations in this document are based on firm evidence and many on experience. The recommendations are considered to represent best practice for the prevention and control of *B. cepacia* complex infection with the present state of our knowledge; it is hoped that they may serve to provide some guidance for local policies. It is intended that the present recommendations will be revised every two years to take account of new developments.

Regular expert microbiological surveillance of people with CF is recommended if spread of a transmissible organism amongst patients is to be identified and dealt with at an early stage. For this, expert microbiological laboratory services are required by the clinic. The reference laboratories mentioned in the document are prepared, after discussion, to examine cultures from Specialist CF Centres and CF Clinics who wish to confirm whether they have a *B. cepacia* complex isolate and whether this may be a known cross-infecting strain.

Finally, the ultimate responsibility for the infection control policy in an individual clinic lies with the clinic director and staff in consultation with their microbiologist and their hospital infection control committee; together they can decide on the precise precautions that are appropriate and necessary in their particular clinic.

The UK Cystic Fibrosis Trust Infection Control Group
September 2004

Grading scheme for recommendations used in The *Burkholderia cepacia* Complex

The criteria for the grading of recommendations in this document are based upon a paper by Petrie et al published on behalf of the Scottish Intercollegiate Guidelines Network.

Much of the data in the document are derived from observational studies where randomisation is not appropriate or possible, but many are from peer-reviewed scientific studies therefore this grading is not always appropriate.

Levels of evidence

<i>Level</i>	<i>Type of evidence (based on AHCPR, 1992)</i>
Ia	Evidence obtained from meta-analysis of randomised controlled trials.
Ib	Evidence obtained from at least one randomised controlled trial.
IIa	Evidence obtained from at least one well designed controlled study without randomisation.
IIb	Evidence for at least one other type of quasi-experimental study.
III	Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case control studies.
IV	Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities.

Grading of recommendations

<i>Grade</i>	<i>Type of recommendation (based on AHCPR, 1992)</i>
A (levels Ia, Ib)	Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.
B (levels IIa, IIb, III)	Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of the recommendation.
C (level IV)	Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality.

Petrie GJ, Barnwell E, Grimshaw J, on behalf of the Scottish Intercollegiate Guidelines Network. *Clinical guidelines: criteria for appraisal for national use*. Edinburgh: Royal College of Physicians, 1995.

Agency for Health Care Policy and Research. *Acute pain management, operative or medical procedures and trauma 92-0032. Clinical practice guidelines*. Rockville, Maryland, USA: Agency for Healthcare Policy and Research Publications, 1992.

SUMMARY

This is a summary of the recommendations of the UK Cystic Fibrosis Trust Infection Control Group to reduce the possibility of people with cystic fibrosis (CF) transmitting from person to person the bacteria of the *Burkholderia cepacia* complex (Bcc), which includes *Burkholderia cenocepacia*. The document contains up-to-date information about Bcc and how these bacteria can affect people with cystic fibrosis. It also gives advice to help reduce the risk of people with CF catching these bacteria from each other. Because Bcc bacteria can be acquired during activities where people with CF meet together outside the hospital, this statement describes what we know about the relative risks of various kinds of activity.

The most important points are listed below but please refer to the full document for more detailed information.

- People with CF who have Bcc infection have more problems with their chest and some become very ill - so it is better to prevent infection with these bacteria. Some people with CF contract Bcc infection and remain quite stable.
- Bcc bacteria do not usually cause infection in healthy people.
- All people with CF should know which bacteria they have in their sputum, and sputum should be checked (cultured) regularly at the Specialist CF Centre or CF Clinic.
- Bcc affects only a minority of people with CF and is mostly caused by passing the infection from person to person.
- Close contact such as sharing rooms, sharing nebuliser equipment, kissing or coughing close to another person with CF are activities which are high risk for passing bacteria from person to person.
- Cross-infection can be significantly reduced by keeping people with CF who are infected with Bcc bacteria apart from others with CF, not only in hospital but also outside of hospital, and by careful attention to good hygiene such as hand washing.
- People with Bcc infection should not attend meetings where there are other people with CF and should not mix with other people with Bcc who may be carrying a different type of Bcc bacteria.

Unfortunately, there is still a great deal we do not know about Bcc bacteria, and this document cannot hope to cover everybody's individual circumstances. If you have further questions about Bcc bacteria please discuss them with staff at the Specialist CF Centre or CF Clinic or contact the Cystic Fibrosis Trust.

I. HISTORICAL PERSPECTIVE

In the late 1970s and early 1980s, an increasing incidence and prevalence of *Burkholderia cepacia* isolates was reported in North American CF Centres (Isles et al, 1984 [III]; Thomassen et al, 1985 [III]). Those people with CF with *B. cepacia* infection were noted to have an increased morbidity and mortality (Tablan et al, 1985 [III] and 1987 [III]; Muhdi et al, 1996 [III]). Subsequent studies using molecular fingerprinting techniques established compelling evidence of cross-infection, including direct patient-to-patient spread via contacts within Specialist CF Centres and outside of clinics through social contacts (LiPuma et al, 1990 [III]; Govan et al, 1993 [III]; Smith et al, 1993 [III]; Millar-Jones et al, 1992 [III]; Cazzola et al, 1996 [III]; Pegues et al, 1994a and 1994b [III] Millar-Jones et al, 1998 [III]). However, a review of 23 published studies (Govan et al, 1996 [IV]) showed that cross-infection was not inevitable, even in the case of siblings with CF, suggesting that spread might be strain-dependent.

The introduction of strict segregation policies led to a dramatic fall in incidence of cross-infection at Specialist CF Centres (Thomassen et al, 1986 [III]; Muhdi et al, 1996 [III]). A longitudinal case-controlled study in Mississippi covering the period 1988-1993 demonstrated that *B. cepacia* could be transmitted between patients with and without cystic fibrosis (Holmes et al, 1999 [III]). The observation that existing *B. cepacia* infection could be replaced with more virulent and transmissible strains further influenced the cohorting of *B. cepacia*-positive people. Transmission however did not appear to be inevitable since several contemporary studies found no evidence of cross-infection (Glass & Govan, 1986 [III]; Hardy et al, 1986 [III]; Taylor et al, 1992 [III]; Steinbach et al, 1994 [III]). In 1997 a seminal taxonomic study revealed that isolates previously identified as *B. cepacia* comprised a complex of multiple closely related species or genomovars (Vandamme et al, 1997 [III]).

2. TAXONOMY OF THE *BURKHOLDERIA CEPACIA* COMPLEX

Since 1997, the taxonomy of *B. cepacia* has undergone major revisions. The use of polyphasic analyses including DNA/DNA hybridization, whole cell protein analyses (Vandamme et al, 1997 [III]) and later *recA* polymerase chain reaction (PCR) (Mahenthiralingam et al, 2000a [III]; Vermis et al, 2002 [III]) have shown that organisms previously identified as *B. cepacia* comprise multiple distinct but closely related genomic species, or genomovars. As a group, these bacteria are referred to as the *B. cepacia* complex. Currently 9 genomovars of the *B. cepacia* complex have been described (Coenye et al, 2001a [III]). To comply with the rules of taxonomic nomenclature, genomovar I retains the original designation of “*B. cepacia*”; other Bcc members are then provided with new or previously designated species names as appropriate. For the purpose of this document, the term Bcc will be used to refer to Bcc collectively, and to describe isolates referred to as “*B. cepacia*” prior to 1997.

***Burkholderia cepacia* complex**

Genomovar I	<i>Burkholderia cepacia</i>
Genomovar II	<i>Burkholderia multivorans</i>
Genomovar III (a, b, etc)	<i>Burkholderia cenocepacia</i>
Genomovar IV	<i>Burkholderia stabilis</i>
Genomovar V	<i>Burkholderia vietnamiensis</i>
Genomovar VI	<i>Burkholderia dolosa</i>
Genomovar VII	<i>Burkholderia ambifaria</i>
Genomovar VIII	<i>Burkholderia anthinia</i>
Genomovar IX	<i>Burkholderia pyrrocinia</i>

3. CLINICAL CONSEQUENCES OF BURKHOLDERIA CEPACIA COMPLEX INFECTION IN PEOPLE WITH CYSTIC FIBROSIS

Burkholderia cepacia complex infection is associated with an increased morbidity and shortened life-expectancy for people with cystic fibrosis. However some people with Bcc remain stable for many years and in some the infection may be transient (Govan et al, 1996 [IV]). It is important to note, however, that clinical outcome varies even in patients infected with the same cluster strain, including the intercontinental strain ET12 (Govan et al, 1993 [III]), and the unique Australian Hunter strain (Fitzgerald et al, 2001 [III]). Clinical outcome is also variable in patients infected with subgroups of the *B. cepacia* complex (Soni et al, 2002 [III]).

- Isles et al, reported 7 deaths in 18 patients with Bcc infection, compared with 4 deaths in 67 patients without *B. cepacia* infection, although the Bcc-positive patients were older and had worse lung function (Isles et al, 1984 [III]).
- In Vancouver patients with Bcc infection were more likely to be hospitalised for longer and died sooner than controls (Tablan et al, 1985 [III]).
- In Cleveland paediatric patients with Bcc infection had a decreased survival in comparison to Bcc-negative patients matched by Shwachman clinical scores; this was particularly so for patients with moderate or advanced lung disease who then acquired *B. cepacia* infection (Tablan et al, 1987 [III]).
- In Birmingham UK, the number of inpatient days and outpatient visits increased following acquisition of Bcc infection in comparison with controls; 61% of patients with Bcc infection died compared with 31% of controls (Muhdi et al, 1996 [III]).
- Frangolias et al compared patients with and without Bcc infection matched by age, sex, pancreatic status and respiratory function (FEV₁ percent predicted). At long-term follow-up, the Bcc-negative patients had a significant survival advantage (Frangolias et al, 1999 [III]).
- In the Canadian CF Registry data, *B. cepacia* was associated with increased mortality at all levels of pulmonary function (Corey & Farewell, 1996 [III]).
- Patients with the highly transmissible *B. cenocepacia* strain ET12 (belonging to genomovar IIIa) were shown to have a fourfold risk of mortality greater than those with *Pseudomonas aeruginosa* infection who attended the same UK Specialist CF Centre (Ledson et al, 2002 [III]).
- In Vancouver, 20 of 46 patients with *B. cenocepacia* infection died in comparison with only 3 of 19 with *B. multivorans* infection. Furthermore, 2 of the latter 3 patients were subsequently superinfected with *B. cenocepacia* before they died (Mahenthiralingam et al, 2001 [III]).
- In Sydney, an actuarial survival study of 15 Bcc-infected patients found that infection had a significant adverse effect on survival with a mortality rate of 40% compared with 17% for the entire clinic population (Soni et al, 2002 [III]).

3.1 Lung Transplantation

- One-year post-transplant survival for people with CF was 67% for Bcc-infected patients and 92% for Bcc-negative patients at a North American Centre (Chaparro et al, 2001 [III]).
- At a UK transplant centre, 5 of 11 patients with Bcc infection died post-transplant because of progressive Bcc-related related sepsis; the 4 isolates that were available for genomovar analysis were all found to be *B. cenocepacia* and were a single strain, namely ET12. None of the 5 available Bcc complex isolates from the 6 patients who survived were *B. cenocepacia* (De Soya et al, 2001 [III]).
- There was a significant excess mortality for patients with CF infected pre-operatively with Bcc than those not infected (33% v 12%). Patients with *B. cenocepacia* infection were at the highest risk of death: 5 of 12 died in comparison with 0 of 8 for other Bcc genomovars. An important observation in this study was that each *B. cenocepacia* death was caused by a unique genotype indicating that increased mortality was related to the species rather than a particular strain (Aris et al, 2001 [III]).
- Modifications to surgical and peri-transplant therapy may improve the outcome in Bcc-infected people with CF, including those infected with *B. cenocepacia* ET12 (Chaparro et al, 2001 [IV]; De Soya et al, 2001 [IV]; De Soya et al, 2004 [IV]).

3.2 Cepacia syndrome

- Isles et al first described a syndrome of a fulminant pneumonia in association with Bcc infection characterised by high fever, leucocytosis, sepsis and severe progressive respiratory failure (Isles et al, 1984 [III]; Tablan et al, 1985 [III]). Although Isles et al did not specifically use the term, this rapid and life-threatening outcome of Bcc infection, with a particularly poor prognosis, has become known as ‘cepacia syndrome’.
- Although thought to be primarily associated with *B. cenocepacia* strains, cepacia syndrome can occur with *B. multivorans* and other members of the *B. cepacia* complex (Mahenthiralingam et al, 2001 [III]; Jones & Webb, 2003 [III]).

Summary

Previous clinical studies have shown that Bcc infection is associated with an increased morbidity and mortality for people with cystic fibrosis. The relative virulence of individual Bcc species, and strains within a species, remains unclear. However evidence suggests that *B. cenocepacia* is the species with the greatest potential virulence for people with cystic fibrosis. Decreased survival of Bcc patients post-transplantation seems particularly associated, though not exclusively, with prior *B. cenocepacia* infection. Modifications to surgical and peri- and post-transplant medical therapy may improve outcome for this group of patients. People with *B. cenocepacia* and *B. multivorans* should still be considered for transplantation but in the light of other risk factors.

4. CROSS-INFECTION CONTROL

The risk of Bcc cross-infection, caused by direct or indirect contacts, is related to a number of factors, including patient behaviour, infection control practices and the particular Bcc species and strains involved.

- The emergence and spread of highly transmissible Bcc strains (sometimes referred to as lineages) resulted in an increase in the incidence and prevalence of *B. cepacia* infection at many Specialist CF Centres during the past two decades. The spread, at national and intercontinental level, of the *B. cenocepacia* strain ET12 (Govan et al, 1993 [III]; Johnson et al, 1994 [III]; Govan et al, 1996, [IV]; Pitt et al, 1996 [III]) has strongly influenced Bcc epidemiology. This factor provides an important caveat in attempts to generalise on Bcc issues. What is certain is the compelling evidence of the spread of transmissible strains within and between Specialist CF Centres (Govan et al, 1993 [III]; Smith et al, 1993 [III]; Johnson et al, 1994 [III]; Whiteford et al, 1995 [III]; Segonds et al, 1997 [III]; Govan et al, 1996 [IV]).
- There is also compelling evidence for patient-to-patient spread of Bcc outside Specialist CF Centres, CF Clinics and hospitals e.g. through attendance at summer camps and other forms of regular social contact (LiPuma et al, 1990 [III]; Govan et al, 1993 [III]; Smith et al, 1993 [III]; Pegues et al, 1994a [III]).
- Individual host factors, including polymorphisms in mannose binding lectins may affect susceptibility to Bcc infection (Garred et al, 1999 [III]; Davies et al, 2000 [III]).
- The introduction of strict segregation policies by Specialist CF Centres has helped to limit *B. cepacia* cross-infection (Thomassen et al, 1986 [III]; Govan et al, 1993 [III]; Muhdi et al, 1996 [III]; Govan, 2000 [IV]). It is important to note that segregation does not eliminate entirely the risk of Bcc acquisition from natural environmental reservoirs.
- In the early 1990s, Bcc-positive patients were cohorted together irrespective of Bcc strain involved. Subsequently, superinfection, in which a new strain replaces an existing Bcc strain, was reported. One UK Specialist CF Centre reported 5 cases in which *B. cenocepacia* ET12 replaced existing Bcc strains with serious consequences; 4 patients subsequently died, 3 from cepacia syndrome (Ledson et al, 1998 [III]).
- In Vancouver, 6 cases of superinfection occurred before species-dependent segregation was introduced. *B. cenocepacia* strains replaced *B. multivorans* with worsening of the clinical condition of the patient (Mahenthalingam et al, 2001 [III]). The clinical relevance of superinfection appears to be influenced by the Bcc species and strain involved. Pulmonary exacerbations with Bcc and *Pseudomonas aeruginosa* are no more severe than when only Bcc was isolated (McManus et al, 2003 [III]).

Summary

Although it causes considerable anxiety and psychosocial consequences, segregating Bcc-positive patients has reduced the spread of highly transmissible *Burkholderia cepacia* complex. Segregation cannot however prevent occasional acquisition of Bcc from the natural environment. The risk of superinfection has highlighted the need to extend cohort segregation of people with CF with Bcc to take account of the species and strain involved.

5. GENERAL ENVIRONMENT AND BURKHOLDERIA CEPACIA COMPLEX

Stringent infection control policies have helped to limit cross-infection, but have not eliminated entirely the risk of sporadic acquisition of Bcc from natural environmental reservoirs. In the absence of human commensal carriage of Bcc, it is often assumed that sporadic cases of Bcc infection occur following contact with an environmental source. This is probably true; however, it is difficult to provide unequivocal evidence for this assumption.

- The precise environmental niches of Bcc thought to be responsible for human infections, including those in people with CF, are unclear. The natural habitats of Bcc species are soils, the plant rhizosphere (the region of soil in the vicinity of plant roots) and freshwater environments such as river sediments (Fisher et al, 1993 [III]; Butler et al, 1995 [III]; Balandreau et al, 2001 [III]; Fiore et al, 2001 [III]; Miller et al, 2002 [III]; Vermis et al, 2003 [III]). Early studies reported low isolation rates for Bcc from a range of natural environments (Butler et al, 1995 [III]; Fisher et al, 1993 [III]). However, the use of improved selective culture has shown that Bcc bacteria are relatively common in such environments (Balandreau et al, 2001 [III]; Fiore et al, 2001 [III]; Miller et al, 2002 [III]; Vermis et al, 2003 [III]). There is also evidence of a close relationship between environmental and clinical isolates. The use of genomic fingerprinting demonstrated a clonal relationship between a plant isolate of *B. cepacia* and an isolate from a person with cystic fibrosis (Govan et al, 2000 [IV]); also a highly transmissible *B. cenocepacia* strain has been identified in soil samples from a field in the USA (LiPuma et al, 2002 [III]).
- *Burkholderia multivorans* is rarely isolated from the natural environment but is one of the two most common Bcc species in isolates from CF sputum (Agodi et al, 2001 [III]; Mahenthiralingam et al, 2002 [III]).
- *Burkholderia cepacia* complex bacteria were rarely isolated in an environmental screening study of a hospital CF ward (Doring et al, 1996 [III]).
- *Burkholderia cepacia* complex bacteria were isolated in only 5 of 916 isolates cultured from homes of people both with and without cystic fibrosis (Mortensen et al, 1995 [III]).
- *Burkholderia cepacia* complex was isolated from 3 of 35 home-use nebulisers. Patients who followed recommended instructions for good nebuliser hygienic practice and paid particular attention to drying had minimal or no contamination of their nebulisers. Of the three cases where Bcc was cultured from a nebuliser, in only one case was the same strain present in the sputum of that patient (Hutchinson et al, 1996 [III]).
- *Burkholderia cepacia* complex can survive on skin for up to 30 minutes, on sputum-contaminated surfaces for weeks and in distilled water for many years (Govan, 2000 [IV]). Strain-to-strain differences in survival have also been demonstrated (Drabick et al, 1996 [III]).
- An air sampling study showed the presence of Bcc in room air in 5 of 6 rooms occupied by Bcc-positive people with cystic fibrosis. Bcc persisted in room air on 4 occasions after the patient left the room; on one occasion for up to 45 minutes (Humphreys et al, 1994 [III]). A further study showed that air samples were more likely to be Bcc-positive after airway clearance (47%) than before (16%) (Ensor et al, 1996 [III]).

Summary

Although Bcc has been isolated from various environmental sources the risk of acquisition from the general environment is low.

6. TRANSMISSIBILITY MARKERS

- Accumulated evidence suggests that transmissibility of Bcc organisms is influenced by strain and species. Most previous Bcc outbreaks have been associated with *B. cenocepacia*, and the ET12 strain in particular (Govan et al, 1996 [IV]; Mahenthiralingam et al, 2001 [III]). However, cross-infection involving *B. multivorans* and other genomovars has also been reported (Whiteford et al, 1995 [III]; Agodi et al, 2001 [III]; Mahenthiralingam et al, 2002 [III]; Segonds et al, 1999 [III]).
- The well-described transmissible *B. cenocepacia* strain, ET12, possesses a gene (*cbIA*) that encodes for the major structural subunit of cable-like and mucin binding pili (Sun et al, 1995 [III]). A DNA marker, known as *Burkholderia cepacia* epidemic strain marker (BCESM), has also been identified in a number of transmissible *B. cenocepacia* strains (Mahenthiralingam et al, 1997 [III]; Baldwin et al, 2004 [III]). BCESM and *cbIA* are not found in all transmissible Bcc strains (Agodi et al, 2001 [III]; LiPuma et al, 2001 [III]) and their absence does not equate with lack of transmissibility. *Burkholderia cenocepacia* ET12 appears to be unique in possessing both markers.

Following accurate laboratory identification, genomic fingerprinting of Bcc to identify strain relationships is a major requirement for epidemiological studies and for infection control surveillance. At present pulsed-field gel electrophoresis (PFGE) is the gold standard. In future, PFGE may be augmented or replaced by multilocus sequence typing.

7. TRANSIENT INFECTION

Some people with cystic fibrosis may acquire transient infection with Bcc but it is more common with *B. multivorans* and other Bcc species than with *B. cenocepacia* (Mahenthiralingam et al, 2001 [III]; Jones & Webb, 2003 [IV]).

When a patient can be declared free of infection, and therefore potentially allowed to mix with other Bcc-negative people with CF, can be a difficult clinical dilemma.

Recommendations

- *Before a person with CF can be considered as being free from Bcc there should be evidence of at least 3 negative sputum cultures over a period of at least one year [C].*
- *Until considered free of infection patients should remain segregated from other people with cystic fibrosis [C].*

8. SUMMARY OF PRESENT CLINICAL KNOWLEDGE OF INDIVIDUAL BURKHOLDERIA CEPACIA COMPLEX SPECIES

In CF Centres in Europe and North America, there is a variable prevalence of Bcc species (Agodi et al, 2001 [III]; LiPuma et al, 2001 [III]; Mahenthiralingam et al, 2002 [III]; Speert et al, 2002 [III]; Drevinek et al, 2002 [III]). Approximately 90% of Bcc isolates from CF sputum can be identified as *B. multivorans* and *B. cenocepacia*. The clinical significance of individual species within the Bcc is still largely unknown. Whilst most transmissible strains belong to *B. cenocepacia*, cross-infection outbreaks relating to other Bcc species, in particular *B. multivorans* have been reported in people with cystic fibrosis (Whiteford et al, 1995 [III]; Segonds et al, 1999 [III]; Agodi et al, 2001 [III]).

8.1 *Burkholderia cenocepacia*

- Is one of the most common Bcc species isolated from CF sputum.
- Can be isolated from the natural environments, particularly agricultural soil.
- The majority of Bcc strains associated with cross-infection between people with CF are *B. cenocepacia* strains.
- Cepacia syndrome is more commonly associated with *B. cenocepacia* than other Bcc species.
- With the exception of post-transplantation outcome, it is unclear whether the apparent increased virulence of *B. cenocepacia* amongst Bcc is species and strain dependent. Further data are required to assess the potential virulence of those Bcc species with low prevalence.
- Prior infection with *B. cenocepacia* is strongly associated with a poor post-transplantation outcome (Chaparro et al, 2001 [IV]; De Soyza et al, 2001 [IV]); this appears to be species rather than strain specific (Aris et al, 2001 [IV]). There is evidence that modifications to the peri-transplant surgical and medical care improves the outcome for patients with *B. cenocepacia* infection, including infection with the ET12 strain (De Soyza et al, 2001 [IV]; De Soyza et al, 2004 [IV]).

8.2 *Burkholderia multivorans*

- Is rarely isolated from natural environments but is one of the most common Bcc species isolated from CF sputum.
- UK microbiological surveillance shows that most new cases of *B. multivorans* infection are caused by unique genotypic strains suggesting sporadic acquisition from natural environments (Turton et al, 2003 [III]). Outbreaks of *B. multivorans* cross-infection among people with CF are less frequent than with *B. cenocepacia* but have been described (Whiteford et al, 1995 [III]; Segonds et al, 1999 [III]; Agodi et al, 2001 [III]; Mahenthiralingam et al, 2002 [III]).
- Evidence suggests that the potential for virulence in *B. multivorans* is less than that in *B. cenocepacia*; however, *B. multivorans* can occasionally cause cepacia syndrome (Mahenthiralingam et al, 2001 [III]; Jones & Webb, 2003 [III]).

8.3 Other *Burkholderia cepacia* complex species

- All have been isolated from CF sputum specimens (Mahenthiralingam et al, 2002 [III]).
- Cross-infection outbreaks have been reported with other Bcc species including *B. pyrrocinia* (Campana et al, 2003 [III]).
- At present, there is insufficient evidence to draw firm conclusions as to the relative pathogenicity of other Bcc species.

9. OTHER NON-BURKHOLDERIA CEPACIA COMPLEX BURKHOLDERIA SPECIES

9.1 *Burkholderia gladioli*

- The clinical significance of *B. gladioli* infection in people with cystic fibrosis remains unclear. The first report (Wilsher et al, 1997 [III]) of an adverse clinical outcome following colonisation with *B. gladioli* had to be revised when the organism was subsequently identified as *B. cenocepacia* ET12 (Clode et al, 1999 [III]). *Burkholderia gladioli* can cause chronic infection in people with CF, although the prevalence is thought to be low (Wilsher et al, 1997 [IV]; Barker et al, 1997 [IV]; Jones et al, 2001a [IV]).
- There are currently no published reports of cross-infection with *B. gladioli* among people with cystic fibrosis.

9.2 *Burkholderia mallei* and *Burkholderia pseudomallei*

- *Burkholderia mallei* and *B. pseudomallei* are closely related to the Bcc and are important human pathogens, requiring 'handling' under laboratory category III containment. *Burkholderia mallei* is the agent of equine glanders and is highly virulent in humans; fortunately such infections are extremely rare. *Burkholderia pseudomallei* is the causative agent of melioidosis, a life-threatening human infection found during the rainy season predominantly in the subtropical regions of Southeast Asia and Australia.
- Cases of *B. pseudomallei* infection in people with CF visiting Southeast Asia have been described, in some cases involving co-infection with *B. cepacia* complex (Schulin & Steinmetz, 2001 [III]; Visca et al, 2001 [III]); cases have also been described in New Zealand (Holland et al, 2002 [IV]) and Australia (O'Carroll, et al, 2003 [IV]).

Recommendations

- *Cystic fibrosis clinicians and microbiologists should be aware of the possibility of B. pseudomallei infection in people with CF returning from South East Asia where the organism is endemic [B].*
- *Travelling to such places during the rainy season, when the organisms can be present in soil in high numbers, is not advised for people with cystic fibrosis [B].*

10. LABORATORY IDENTIFICATION OF BURKHOLDERIA CEPACIA COMPLEX

Accurate identification of Bcc from specimens of sputum from people with CF is of the utmost importance. False positive identification has serious psychological, social and organisational consequences; these include exclusion from scientific conferences and social events or rejection as a potential lung transplant recipient. False negative identification could affect the CF community at large by leading to epidemic spread (Miller & Gilligan, 2003 [IV]).

In the clinical microbiology laboratory, the use of selective media and appropriate identification procedures is vital for optimum culture and reliable diagnosis of Bcc in sputum and other clinical specimens (van Pelt et al, 1999 [III]; Miller & Gilligan, 2003 [IV]). Identification of Bcc by common commercial systems is unreliable. When a Bcc strain panel (Mahenthalingam et al, 2000b [III]) was used to evaluate various commercial systems, API 20NE proved to be the most accurate (Govan unpublished data); it was also the only system that identified *B. cenocepacia* ET12 and the *B. multivorans* strain responsible for a serious outbreak in a paediatric Specialist CF Centre (Whiteford et al, 1995 [III]).

- An initial report described cross-infection with *B. gladioli* at a Specialist CF Centre (Wilsher et al, 1997 [III]). It was subsequently shown the species had been misidentified and was in fact *B. cenocepacia* ET12 (Clode et al, 1999 [III]).
- 88 (11%) of 770 CF isolates from 115 US CF Centres sent to the CF Foundation Burkholderia cepacia Research Laboratory and Repository, that had been provisionally identified by referring laboratories as Bcc, were found to have been misidentified. Of a further 281 isolates not specifically identified or identified as another species, 101 (36%) were found to be *Burkholderia cepacia* complex (McMenamin et al, 2000 [III]).
- 34 (12%) of 282 CF isolates from 19 UK Specialist CF Centres sent to the Edinburgh CF Microbiology Laboratory and Strain Repository as Bcc were misidentified. False-negatives were rare, with only one isolate (referred as *Pseudomonas aeruginosa*) identified as *Burkholderia cepacia* complex (Govan unpublished data).

Infection control strategies and laboratory identification for Bcc require an awareness of the problems that may arise in culture and identification, including the consequences of recent taxonomic research pioneered by Peter Vandamme in Gent, Belgium (Vandamme et al, 1997 [IV]). Unless state-of-the-art facilities are available on site, all new isolates suspected as Bcc should be sent to a referral laboratory experienced in the phenotypic and DNA-based identification of the group. To ensure optimum culture and identification of the *B. cepacia* complex from CF respiratory secretions it is *essential* to use selective media** and incubate at 37°C for at least 72 hours. Bacterial colonies tentatively identified as Bcc can be further identified by a multitest commercial system (e.g. API 20NE). The single tube arginine glucose medium provides a simple, inexpensive and reliable screen to reduce the number of false positives after isolation from Bcc selective media, and is particularly useful when large numbers of isolates require investigation (Govan, 1996 [III]). Further tests available on request to National Referral Laboratories at Colindale and Edinburgh*** include identification of individual Bcc species based on specific phenotypic tests and *recA*-based polymerase chain reaction (PCR). PCR identification of epidemic markers (BCESM and *cbIA*) is also available as well as genomic fingerprinting (RAPD, PFGE, MLRT) to investigate clonality of individual isolates for infection control surveillance and other studies.

** See next page for details.

*** See next page for details.

****Recommended selective culture media:**

Mast cepacia agar: Mast Group Ltd, Bootle, UK. L20 1EA
Burkholderia cepacia selective agar (BCSA) (Henry et al, 1997 [III]).

*****National Reference Laboratories at Colindale and Edinburgh**

Laboratory of HealthCare Associated Infection
Specialist and Reference Microbiology Division
Health Protection Agency
61 Colindale Avenue
London NW9 5HT
Deputy Director: Dr Tyrone Pitt
Email: tyrone.pitt@hpa.org.uk
☎ 0208 200 4400 ext 4224

The Cystic Fibrosis Microbiology Laboratory and Strain Repository
Medical Microbiology Division
University of Edinburgh Medical School
Teviot Place
Edinburgh EH8 9AG
Director: Professor John Govan
Email: john.r.w.govan@ed.ac.uk
☎ 0131 650 3164
Lab Manager: Dr Catherine Doherty
Email: catherine.doherty@ed.ac.uk
☎ 0131 650 3162 (Office) 3165 (Lab)

II. TREATMENT – RECENT ADVANCES

Antibiotic susceptibility patterns are strain dependent and strains often exhibit multi-resistance (Nzula et al, 2002 [III]). Treatment should be based on antibiotic sensitivity patterns where these are available and will often involve the use of multiple antibiotics, the choice of which may be aided by synergy testing which is being evaluated (Aaron et al, 2000 [III]; *Antibiotic Treatment for Cystic Fibrosis*. Cystic Fibrosis Trust, 2002 [IV]).

At present, there are no published studies describing regimens for the eradication of early *Burkholderia cepacia* complex infection. A preliminary report using a combination of nebulised amiloride and tobramycin successfully eradicated the organism in 3 of 4 patients (Middleton & Williams, 2004 [IV]).

12. RECOMMENDATIONS TO LIMIT SPREAD

There is compelling evidence that people with CF can acquire Bcc by direct patient-to-patient spread in hospital or during social contacts outside hospital or occasionally via acquisition from contaminated environments. Following the introduction of effective infection control measures most new infections are now with sporadic strains. Current medical opinion is that patients with CF with Bcc infection should be segregated from each other and all other people with cystic fibrosis.

Regular attendance and follow-up at a Specialist CF Centre has been shown to be beneficial to both children and adults (Mahadeva et al, 1998 [III]). Therefore avoiding clinic attendance because of fear of Bcc infection is likely to be harmful in that it may seriously interfere with medical care and far outweigh any potential risk of acquiring new infection - provided adequate infection control measures are in place.

12.1 General

- *Patients and carers should be encouraged to discuss their concerns about infection control measures with the clinic staff [C].*

12.2 Segregation of patients according to their microbiological status

- *Every Specialist CF Centre and CF Clinic, large or small should have a surveillance and infection control policy that considers cross-infection risk [B].*
- *The methods used and extent to which Specialist CF Centres and CF Clinics segregate patients should be determined by local policy based on knowledge of the patient's microbiological status [C].*
- *Good hygiene should be practiced in all outpatient clinics and inpatient facilities to minimise the risk of transmission of Bcc between patients [B].*
- *Regular microbiological surveillance should include specific examination for Bcc organisms. An increase in incidence of Bcc isolations would suggest the presence of a transmissible strain [B].*
- *A policy of segregation should cover both inpatient admissions and outpatient clinics. There should be separate clinics for patients chronically infected with Bcc and those who are Bcc-negative [C].*
- *The Bcc clinics should be held on different days or at a later session to avoid patients meeting and mixing in other departments e.g. laboratory, pharmacy, X-ray, restaurant etc [C].*
- *Bcc patients should be seen in different Bcc clinics according to their genomovar status. Also those with highly transmissible strains and sporadic strains of the same genomovar should be seen separately [C].*

12.3 In the outpatient clinic

Good hygienic measures are of great importance in any clinic. These should form part of the local infection control policy for the hospital, but the following are recommendations for best practice for those dealing with people with cystic fibrosis.

General hygienic measures to limit cross-infection

- *Hand washing, disinfection with alcohol rubs or the use of disposable gloves before and after contact with each patient is recommended to minimise cross-infection [B].*
- *Patients should cover their mouths or noses when coughing or sneezing [B].*
- *Patients should wash or disinfect their hands before use of a spirometer or other handheld apparatus [B].*
- *Respiratory function tests should be performed in a well-ventilated room away from other patients [B].*
- *Local infection control policies should be established to prevent contamination and cross-infection from clinic equipment. This will depend on the nature of the equipment [C].*
- *Sputum specimens and throat swabs should be obtained in a well-ventilated room away from other patients [B].*
- *Sputum pots should be covered and soiled tissues must be disposed of immediately after use in the clinical waste bin. Sputum should not be expectorated down toilets, sinks, and washbasins or in showers [B].*
- *Airway clearance techniques should be carried out in a separate room away from the waiting area [B].*
- *The physiotherapists should take appropriate hygienic precautions to prevent contamination of their hands and clothing with respiratory secretions by the use of disposable aprons [B].*
- *Cleaning of surfaces and apparatus between patients should be specified by local infection control policies [C].*
- *Consideration should be given to the potential for possible cross-infection afforded by toys, books, magazines, computers, game consoles and other communal facilities [C].*
- *Patients with CF should be encouraged to bring their own toys and books and not share them with others with cystic fibrosis [C].*
- *All equipment should be cleaned and dried after use and maintained according to the local infection control policies [B].*
- *Apparatus, stethoscopes, sphygmomanometers, auroscopes etc. should be cleaned between patients [B].*

12.4 Additional recommendations for inpatients

- *All members of medical, paramedical, nursing and other staff who have physical contact with patients should practice hand washing or appropriate disinfection of hands between dealing with different patients. This includes anyone who comes into contact with the patient [C].*
- *Patients should have well-ventilated single rooms of an adequate size and there should be en suite facilities in all rooms [C].*
- *Respiratory function tests, exercise tests, nebulisation and physiotherapy treatment sessions should be carried out either separately in the physiotherapy department, a treatment room or in the patient's own room with the door closed [C].*

- *Patients should have their own nebuliser-compressor system, oxygen therapy delivery devices and airway clearance devices as required. Equipment should not be shared between patients [C].*
- *Sinks, taps and showers should be cleaned according to local infection control policies [C].*
- *Eating and drinking utensils and sweets should not be shared between patients [C].*
- *Food should be consumed in the patients' rooms rather than at a communal table [C].*
- *Rooms should be cleaned between patients according to local infection control policies [C].*
- *Grouping of children with CF for hospital schooling arrangements is no longer appropriate [C].*
- *Bcc patients should be nursed on different wards according to genomovar status, and on different wards to non-Bcc patients [B].*

12.5 Away from the hospital

Casual meetings between people with CF, including brief encounters indoors and outdoors, carry a small risk of infection and this risk is increased the longer and closer the contact.

- *Patients should discuss cross-infection issues with their physician and CF Team and be aware of their own microbiological status [C].*
- *All communal CF camps and holidays should be avoided [B].*
- *Spa and other forms of aerated baths should be avoided [B].*
- *Schooling: although there are a few reports that Bcc infection can be transmitted between children in the school environment, it is preferable for children with CF attending the same school to be in different classes; if possible they should attend different schools [C].*
- *Higher education: students should be aware of their microbiological status and are advised to discuss this with their CF physician, the student health service (which then has legal responsibility) and their personal tutor [C].*
- *Workplace: people with CF should be aware of their microbiological status and are advised to discuss this with their CF physician and occupational health services who can then take appropriate action to minimise the risk of cross-infection [C].*
- *Siblings with CF should have separate bedrooms and should perform their airway clearance and other treatments separately [C].*

13. RISKS OF VARIOUS FORMS OF SOCIAL CONTACT

The exact risk associated with each different type of social contact is unknown and depends on the likelihood of transferring respiratory secretions. It would be wrong to deliberately expose patients to Bcc to find out. However, it is known that the risk of being infected increases with closer types of contact, with the duration of contact and when strains with known epidemic potential, such as *B. cenocepacia* ET12, are involved. The degree of risk associated with some typical situations can be estimated. Contacts that do not last very long, or do not occur very often, are less risky than contacts, which are prolonged or frequent. Outdoor events are thought to be less risky than indoor events provided good hygiene is observed.

13.1 Table: Activities shared with other people with cystic fibrosis: Risk of transmission

Brief encounters indoors or outdoors	Low
Closer social contact – evenings in the pub or restaurant	High
Hand shaking	High
Contacts involving siblings with cystic fibrosis	High
Sharing bedrooms	High
Social kissing	High
Travelling together in closed conditions e.g. car or lift	High
Sports or exercise classes	High
Sharing eating or drinking utensils	High
Intimate contact - kissing, sexual relationships	High

14. REFERENCES

In addition to the references cited, readers are directed to additional information and updates on the Bcc to be found on the website of the International *Burkholderia cepacia* Working Group (<http://go.to/cepacia>).

There are wide-ranging reviews covering taxonomy, epidemiology, virulence, clinical management and biopesticide use (Govan et al, 1996 [IV]; LiPuma, 1998 [IV]; Speert 2002 [IV]; Mohr et al, 2001 [IV]; Moore & Elborn, 2001 [IV]; Jones, et al, 2001b; [IV]; Coenye et al, 2001b [IV]; Environmental Protection Agency U.S. 2002, [IV]). Guidelines on infection control for Bcc infection are also contained within the comprehensive Society for Healthcare Epidemiology of America [HEA] document (Saiman et al, 2003 [IV]) and a recent review (Saimon & Siegel, 2004). The limited options for antibiotic therapy can be found in *Antibiotic Treatment for Cystic Fibrosis* (Cystic Fibrosis Trust, 2002 [IV]).

NB *Pseudomonas cepacia* is now named *Burkholderia cepacia*. Papers prior to 1995 refer to *Pseudomonas cepacia*.

Agodi A, Mahenthiralingam E, Barchitta M, Giannino V, Sciacca A, Stefani S. *Burkholderia cepacia* complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. *J Clin Microbiol* 2001; 39:2891-2896.

Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with *Burkholderia cepacia* complex. Survival linked to genomovar type. *Am J Resp Crit Care Med* 2001; 164:2102-2106.

Aaron SD, Ferris W, Henry DA, Speert DP, MacDonald NE. Multiple combination antibiotic testing for patients with cystic fibrosis infected with *Burkholderia cepacia*. *Am J Resp Crit Care Med* 2000; 161:1206-1212.

Antibiotic Treatment for Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Group. 2nd Edition Cystic Fibrosis Trust 2002.

Balandreau J, Viallard V, Cournoyer B, Coenye T, Laevens S, Vandamme P. *Burkholderia cepacia* genomovar III is a common plant-associated bacterium. *Appl Environ Microbiol* 2001; 67:982-985.

Baldwin A, Sokol PA, Parkhill J, Mahenthiralingam E. The *Burkholderia cepacia* epidemic strain marker is part of a novel genomic island encoding both virulence and metabolism-associated genes in *Burkholderia cenocepacia*. *Infect Immun* 2004; 72:1537-1547.

Barker PM, Wood RE, Gilligan PH. Lung infection with *Burkholderia gladioli* in a child with cystic fibrosis: acute clinical and spirometric deterioration. *Pediatr Pulmonol* 1997; 23:123-125.

Butler SL, Doherty CJ, Hughes JE, Nelson JW, Govan JR. *Burkholderia cepacia* and cystic fibrosis: do natural environments present a potential hazard? *J Clin Microbiol* 1995; 33:1001-1004.

Campana S, Taccetti G, Ravenni N, Favari F, Cariani L, Sciacca A, et al. Transmission of *Burkholderia pyrrocinia*. a report of two outbreaks involving Italian cystic fibrosis patients. *Pediatr Pulmonol* 2003, Suppl 25:299. Abstract 334.

Cazzola G, Amalfitano G, Tonolli E, Perazzoli C, Piacentini I, Mastella G. *Burkholderia (Pseudomonas) cepacia* epidemiology in a cystic fibrosis population: genome finger-printing study. *Acta Paediatr* 1996; 85:554-557.

Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, et al. Infection with *Burkholderia cepacia* in cystic fibrosis: outcome following lung transplantation. *Am J Resp Crit Care Med* 2001; 163:43-48.

Clode FE, Kaufmann ME, Malnick H, Pitt TL. Evaluation of three oligonucleotide primer sets in PCR for identification of *Burkholderia cepacia* and their differentiation from *Burkholderia gladioli*. *J Clin Path* 1999; 52:173-176.

Coenye T, Vandamme P, Govan JRW, LiPuma JJ. Taxonomy and identification of the *Burkholderia cepacia* complex. *J Clin Microbiol* 2001a; 39:3427-3436.

Coenye T, LiPuma JJ, Henry D, Hoste B, Vandemeulebroecke K, Gillis M et al. *Burkholderia cepacia* genomovar VI, a new member of the *Burkholderia cepacia* complex isolated from cystic fibrosis patients. *Int J System Evolut Microbiol* 2001b; 51:271-279.

Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. *Am J Epidemiol* 1996; 143:1007-1017.

Davies J, Neth O, Alton E, Klein N, Turner M. Differential binding of mannose-binding lectin to respiratory pathogens in cystic fibrosis. *Lancet* 2000; 355:1885-1886.

- De Soyza A, McDowell A, Archer L, Dark JH, Elborn SJ, Mahenthalingam E, et al. *Burkholderia cepacia* complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. *Lancet* 2001; 358:1780-1781.
- De Soyza A, Morris K, McDowell A, Doherty C, Archer L, Perry J, et al. Prevalence and clonality of *Burkholderia cepacia* complex genomovars in United Kingdom cystic fibrosis patients referred for lung transplantation. *Thorax* 2004; 59:526-528.
- Doring G, Jansen S, Noll H, Grupp H, Frank F, Botzenhart K, et al. Distribution and transmission of *Pseudomonas aeruginosa* and *Burkholderia cepacia* in a hospital ward. *Pediatr Pulmonol* 1996; 21:90-100.
- Drabick JA, Gracely EJ, Heidecker GJ, LiPuma JJ. Survival of *Burkholderia cepacia* on environmental surfaces. *J Hosp Infect* 1996; 32:267-276.
- Drevinek P, Hrbackova H, Cinek O, Bartosova J, Nyc O, Nemecek A, et al. Direct PCR detection of *Burkholderia cepacia* complex and identification of its genomovars by using sputum as source of DNA. *J Clin Microbiol* 2002; 40:3485-3488.
- Ensor E, Humphreys H, Peckham D, Webster C, Knox AJ. Is *Burkholderia (Pseudomonas) cepacia* disseminated from cystic fibrosis patients during physiotherapy? *J Hosp Infect* 1996; 32:9-15.
- Environmental Protection Agency. *Burkholderia cepacia* complex: Proposed significant new use rule. *Fed Register* 2002; 67 (January 9th) 1179-1186.
- Fiore A, Laevens S, Bevivino A, Dalmastrì C, Tabacchioni S, Vandamme P, et al. *Burkholderia cepacia* complex: distribution of genomovars among isolates from the maize rhizosphere in Italy. *Environ Microbiol* 2001; 3:137-143.
- Fisher MC, LiPuma JJ, Dasen SE, Caputo GC, Mortensen JE, McGowan KL, et al. Source of *Pseudomonas cepacia*: ribotyping of isolates from patients and from the environment. *J Pediatr* 1993; 123:745-747.
- Fitzgerald DA, Cooper DM, Paul M, Tiley S, Kado J, Cordwell J, et al. *Burkholderia cepacia* in cystic fibrosis: novel Australian cluster strain without accelerated respiratory deterioration. *J Paediatr Child Health* 2001; 37:130-136.
- Frangolias DD, Mahenthalingam E, Rae S, Raboud JM, Davidson AG, Wittmann R, et al. *Burkholderia cepacia* in cystic fibrosis. Variable disease course. *Am J Respir Crit Care Med* 1999; 160:1572-1577.
- Garred P, Pressler T, Madsen HO, Frederiksen B, Svegaard A, Hoiby N, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. *J Clin Invest* 1999; 104:431-437.
- Glass S, Govan JR. *Pseudomonas cepacia* - fatal pulmonary infection in a patient with cystic fibrosis. *J Infect* 1986; 13:157-158.
- Govan JRW. *Pseudomonas, Stenotrophomonas, Burkholderia*. In: JG Collee, AG Fraser, BP Marmion, A Simmons (eds) Mackie & McCartney Practical Medical Microbiology. Edinburgh Churchill Livingstone 14th edit 1996; 413-424.
- Govan JR. Infection control in cystic fibrosis: methicillin-resistant *Staphylococcus aureus*, *Pseudomonas aeruginosa* and the *Burkholderia cepacia* complex. *J R Soc Med* 2000 93 (Suppl 38):40-45.
- Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, et al. Evidence for transmission of *Pseudomonas cepacia* by social contact in cystic fibrosis. *Lancet* 1993; 342:15-19.
- Govan JR, Hughes J, Vandamme P. *Burkholderia cepacia*: medical, taxonomic and ecological issues. *J Med Microbiol* 1996; 45:395-407.
- Govan JRW, Balandreau J, Vandamme P. *Burkholderia cepacia* - friend and foe. *ASM News* 2000; 66; 124-125.
- Hardy KA, McGowan KL, Fisher MC, Schidlow DV. *Pseudomonas cepacia* in the hospital setting: lack of transmission between cystic fibrosis patients. *J Pediatr* 1986; 109:51-54.
- Henry DA, Campbell ME, LiPuma JJ, Speert DP. Identification of *Burkholderia cepacia* isolates from patients with cystic fibrosis and use of a simple new selective medium. *J Clin Microbiol* 1997; 35:614-619.
- Holland DJ, Wesley A, Drinkovic D, Currie BJ. Cystic Fibrosis and *Burkholderia pseudomallei* infection: An Emerging Problem? *Clin Infect Dis* 2002; 35:e138-140.
- Holmes A, Nolan R, Taylor R, Finley R, Riley M, Jiang RZ, et al. An epidemic of *Burkholderia cepacia* transmitted between patients with and without cystic fibrosis. *J Infect Dis* 1999; 179:1197-1205.
- Humphreys H, Peckham D, Patel P, Knox A. Airborne dissemination of *Burkholderia (Pseudomonas) cepacia* from adult patients with cystic fibrosis. *Thorax* 1994; 49:1157-1159.
- Hutchinson GR, Parker S, Pryor JR, Duncan-Skingle F, Hoffman PN, Hodson ME, et al. Home-use nebulizers: a potential primary source of *Burkholderia cepacia* and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. *J Clin Microbiol* 1996; 34:584-587.
- Isles A, Maclusky M, Corey M, Gold C, Prober P, Fleming P, et al. *Pseudomonas cepacia* infection in cystic fibrosis: an emerging problem. *J Pediatr* 1984; 104:206-210.

- Johnson WM, Tyler SD, Rozee KR. Linkage analysis of geographic and clinical clusters in *Pseudomonas cepacia* infections by multilocus enzyme electrophoresis and ribotyping. *J Clin Microbiol* 1994; 32:924-930.
- Jones AM, Stanbridge TN, Isalska BJ, Dodd ME, Webb AK. *Burkholderia gladioli*: recurrent abscesses in a patient with cystic fibrosis. *J Infect* 2001a; 42:69-71
- Jones AM, Dodd ME, Webb AK. *Burkholderia cepacia*: current clinical issues, environmental controversies and ethical dilemmas. *Eur Resp J* 2001b; 17:295-301.
- Jones AM, Webb AK. Recent advances in cross-infection in cystic fibrosis: *Burkholderia cepacia* complex, *Pseudomonas aeruginosa* MRSA and *Pandorea* spp. *J R Soc Med* 2003; 96 (Suppl 43):66-72.
- Ledson, MJ, Gallagher MJ, Corkhill JE, Hart CA, Walshaw MJ. Cross infection between cystic fibrosis patients colonised with *Burkholderia cepacia*. *Thorax* 1998; 53:432-436.
- Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of *Burkholderia cepacia* colonisation in an adult cystic fibrosis centre. *Thorax* 2002; 57:142-145.
- LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL, et al. Person-to-person transmission of *Pseudomonas cepacia* between patients with cystic fibrosis. *Lancet* 1990; 336:1094-1096.
- LiPuma JJ. *Burkholderia cepacia*. Management issues and new insights. *Clinics in Chest Medicine* 1998; 13:473-486.
- LiPuma JJ, Spliker T, Gill LH, Campbell PW, Liu L, Mahenthalingam E. Disproportionate distribution of *Burkholderia cepacia* complex species and transmissibility markers in cystic fibrosis. *Am J Respir Crit Care Med* 2001; 164:92-96.
- LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic *Burkholderia cepacia* complex strain identified in soil. *Lancet* 2002; 359:2002-2003.
- Mahadeva R, Webb K, Westerbeek RC, Carroll NR, Dodd ME, Bilton D, et al. Clinical outcome in relation to care specialising in cystic fibrosis: cross sectional study. *BMJ* 1998; 316:1771-1775.
- Mahenthalingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic *Burkholderia cepacia* strains recovered from patients with cystic fibrosis. *J Clin Microbiol* 1997; 35:808-816.
- Mahenthalingam E, Bischof J, Byrne SK, Radomski C, Davies JE, Av-Gay Y, et al. DNA-Based diagnostic approaches for identification of *Burkholderia cepacia* complex, *Burkholderia vietnamiensis*, *Burkholderia multivorans*, *Burkholderia stabilis*, and *Burkholderia cepacia* genomovars I and III. *J Clin Microbiol* 2000a; 38:3165-3173.
- Mahenthalingam E, Coenye T, Chung JW, Speert DP, Govan JR, Taylor P, et al. Diagnostically and experimentally useful panel of strains from the *Burkholderia cepacia* complex *J Clin Microbiol* 2000b; 38:910-913.
- Mahenthalingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM Wong LT, et al. Infection with *Burkholderia cepacia* complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace *Burkholderia multivorans*. *Clin Infect Dis* 2001; 33:1469-1475.
- Mahenthalingam E, Baldwin A, Vandamme P. *Burkholderia cepacia* complex infection in patients with cystic fibrosis. *J Med Microbiol* 2002; 51:533-538.
- McManus TE, Moore JE, Crowe M, Dunbar K, Elborn JS. A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic *Burkholderia cepacia* infection. *J Infect* 2003; 46:56-59.
- McMenamin JD, Zaccane TM, Coenye T, Vandamme P, LiPuma JJ. Misidentification of *Burkholderia cepacia* in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. *Chest* 2000; 117:1661-1665.
- Middleton PG, Williams B. Combination aerosol therapy can eradicate *Burkholderia cepacia* complex from CF adults. *J Cystic Fibrosis* 2004; 3 (Suppl 1): S36. Poster 129.
- Millar-Jones L, Paull A, Saunders Z, Goodchild MC. Transmission of *Pseudomonas cepacia* among cystic fibrosis patients. *Lancet* 1992; 340:491.
- Millar-Jones L, Ryley HC, Paull A, Goochild MC. Transmission of *Burkholderia cepacia* in Welsh cystic fibrosis subjects. *Respir Med* 1998; 92:178-183.
- Miller SC, LiPuma JJ, Parke J. Culture-based and non-growth-dependent detection of the *Burkholderia cepacia* complex in soil environments. *Appl Environ Microbiol* 2002; 68:3750-3758.
- Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. *J Clin Microbiol* 2003; 41:4009-4015.
- Mohr CD, Tomich M, Herfst CA. Cellular aspects of *Burkholderia cepacia* infection. *Microbes Infect.* 2001; 3:425-435.
- Moore JE, Elborn JS. *Burkholderia cepacia* and cystic fibrosis - 50 years on. *Commun Dis Public Health* 2001; 4:114-116.
- Mortensen JE, Fisher MC, LiPuma JJ. Recovery of *Pseudomonas cepacia* and other *Pseudomonas* species from the environment. *Inf Contr Hosp Epidemiol* 1995; 16:30-32.

- Muhdi K, Edenborough FP, Gumery L, O'Hickey S, Smith EG, Smith DL, et al. Outcome for patients colonised with *Burkholderia cepacia* in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. *Thorax* 1996; 51:374-377.
- Nzula S, Vandamme P, Govan JR, Influence of taxonomic status on the *in vitro* antimicrobial susceptibility of the *Burkholderia cepacia* complex. *J Antimicrob Chemother* 2002; 50:265-269.
- O'Carroll MR, Kidd TJ, Coulter C, Smith HV, Rose BR, Harbour C, et al. *Burkholderia pseudomallei*: another emerging pathogen in cystic fibrosis. *Thorax* 2003; 58:1087-1091.
- Pegues DA, Carson LA, Tablan OC, FitzSimmons SC, Roman SB, Miller JM, et al. Acquisition of *Pseudomonas cepacia* at summer camps for patients with cystic fibrosis. Summer Camp Study Group. *J Pediatr* 1994a; 124:694-702.
- Pegues DA, Schidlow DV, Tablan OC, Carson LA, Clark NC, Jarvis WR. Possible nosocomial transmission of *Pseudomonas cepacia* in patients with cystic fibrosis. *Arch Pediatr Adolesc Med* 1994b; 148:805-812
- Pitt TL, Kaufmann ME, Patel PS, Benge LC, Gaskin S, Livermore DM. Type characterisation and antibiotic susceptibility of *Burkholderia (Pseudomonas) cepacia* isolates from patients with cystic fibrosis in the United Kingdom and Republic of Ireland. *J Med Microbiol* 1996; 44:203-210.
- Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection Control Recommendations for Patients with Cystic Fibrosis: Microbiology, Important Pathogens, and Infection Control Practices to Prevent Patient-to-Patient Transmission. *Am J Infect Control* 2003; 24 Suppl:S1-S52.
- Saiman L, Siegel J. Infection control in cystic fibrosis. *Clin Microbiol Rev* 2004;17:57-71.
- Schulin T, Steinmetz I. Chronic melioidosis in a patient with cystic fibrosis. *J Clin Microbiol* 2001; 39:1676-1677.
- Segonds C, Bingen E, Couetdic G, Mathy S, Brahimi N, Marty N, et al. Genotypic analysis of *Burkholderia cepacia* isolates from 13 French cystic fibrosis centers. *J Clin Microbiol* 1997; 35:2055-2060.
- Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of *Burkholderia* species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. *J Clin Microbiol* 1999; 37:2201-2208.
- Smith DL, Gumery LB, Smith EG, Stableforth DE, Kaufmann ME, Pitt TL. Epidemic of *Pseudomonas cepacia* in an adult cystic fibrosis unit: evidence of person-to-person transmission. *J Clin Microbiol* 1993; 31:3017-3022.
- Soni R, Marks G, Henry DA, Robinson M, Moriarty C, Parsons S, et al. Effect of *Burkholderia* infection in the clinical course of patients with cystic fibrosis: a pilot study in a Sydney clinic. *Respirology* 2002; 7:241-245.
- Speert DP, Henry D, Vandamme P, Corey M, Mahenthalingam E. Epidemiology of *Burkholderia cepacia* complex in patients with cystic fibrosis, Canada. *Emerg Infect Dis* 2002; 8:181-187.
- Speert DP. Advances in *Burkholderia cepacia* complex. *Paediatr Resp Rev* 2002; 3:230-235.
- Steinbach S, Sun L, Jian R-Z, Flume P, Gilligan P, Egan TM. Transmissibility of *Pseudomonas cepacia* infection in clinic patients and lung-transplant recipients with cystic fibrosis. *N Engl J Med* 1994; 331:981-987.
- Sun L, Jiang RZ, Steinbach S, Holmes A, Campanelli C, Forstner J, et al. The emergence of a highly transmissible lineage of cbl+ *Pseudomonas (Burkholderia) cepacia* causing CF centre epidemics in North America and Britain. *Nat Med* 1995; 1:661-666.
- Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, et al. *Pseudomonas cepacia* colonization in patients with cystic fibrosis: risk factors and clinical outcome. *J Pediatr* 1985; 107:382-387.
- Tablan OC, Martone WJ, Doershuk CF, Stern RC, Thomassen MJ, Klinger JD, et al. Colonization of the respiratory tract with *Pseudomonas cepacia* in cystic fibrosis. Risk factors and outcomes. *Chest* 1987; 91:527-532.
- Taylor RF, Dalla Costa L, Kaufmann ME, Pitt TL, Hodson ME. *Pseudomonas cepacia* pulmonary infection in adults with cystic fibrosis: is nosocomial spread occurring? *J Hosp Infect* 1992; 21:199-204.
- Thomassen MJ, Demko CA, Klinger JD, Stern RC. *Pseudomonas cepacia* colonization among patients with cystic fibrosis. A new opportunist. *Am Rev Respir Dis* 1985; 131:791-796.
- Thomassen MJ, Demko CA, Doershuk CF, Stern RC, Klinger JD. *Pseudomonas cepacia*: decrease in colonization in patients with cystic fibrosis. *Am Rev Respir Dis* 1986 134:669-671.
- Turton JF, Kaufmann ME, Mustafa N, Kawa S, Clode FE, Pitt TL. Molecular comparison of isolates of *Burkholderia multivorans* from patients with cystic fibrosis in the United Kingdom. *J Clin Microbiol* 2003; 41:5750-5754.
- van Pelt C, Veruin CM, Goessens WHE, Vos MC, Tummler B, Segonds C, et al. Identification of *Burkholderia* spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. *J Clin Microbiol* 1999; 37:2158-2164.
- Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R, et al. Occurrence of multiple genomovars of *Burkholderia cepacia* in cystic fibrosis patients and proposal of *Burkholderia multivorans* sp. nov. *Int J Syst Bacteriol* 1997; 47:1188-1200.

- Vermis K, Coenye T, Mahenthalingam E, Nelis HJ, Vandamme P. Evaluation of species-specific recA-based PCR tests for genomovar level identification within the *Burkholderia cepacia* complex. J Med Microbiol 2002; 51:937-940.
- Vermis K, Brachkova M, Vandamme P, Nelis HJ. Isolation of *Burkholderia cepacia* complex genomovars from waters. Syst Appl Microbiol 2003; 26:595-600.
- Visca P, Cazzola G, Petrucca A, Braggion C. Travel-associated *Burkholderia pseudomallei* infection (Meliodosis) in a patient with cystic fibrosis: a case report. Clin Infect Dis 2001; 32:15-16.
- Whiteford ML, Wilkinson JD, McColl JH, Conlon FM, Michie JR, Evans TJ, et al. Outcome of *Burkholderia (Pseudomonas) cepacia* colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995; 50:1194-1198.
- Wilsher ML, Kolbe J, Morris AJ, Welch DF. Nosocomial acquisition of *Burkholderia gladioli* in patients with cystic fibrosis. Am J Resp Crit Care Med 1997; 156:1436-1440.

Notes



Cystic Fibrosis Trust
11 London Road
Bromley
Kent BR1 1BY

Tel: 020 8464 7211

Fax: 020 8313 0472

enquiries@cftrust.org.uk

www.cftrust.org.uk

ISBN 0-9540536-8-0